Lineage Cell Therapeutics, Inc. (LCTX)
| Market Cap | 388.58M |
| Revenue (ttm) | 14.56M |
| Net Income (ttm) | -63.53M |
| Shares Out | 249.09M |
| EPS (ttm) | -0.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,307,552 |
| Open | 1.560 |
| Previous Close | 1.550 |
| Day's Range | 1.531 - 1.660 |
| 52-Week Range | 0.425 - 2.090 |
| Beta | 1.80 |
| Analysts | Strong Buy |
| Price Target | 6.25 (+300.64%) |
| Earnings Date | May 14, 2026 |
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It a... [Read more]
Financial Performance
In 2025, Lineage Cell Therapeutics's revenue was $14.56 million, an increase of 53.24% compared to the previous year's $9.50 million. Losses were -$63.53 million, 241.4% more than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for LCTX stock is "Strong Buy." The 12-month stock price target is $6.25, which is an increase of 300.64% from the latest price.
News
Lineage Announces Formation of Scientific Advisory Board
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics Earnings Call Transcript: Q4 2025
Key milestones achieved in cell therapy programs, with expanded clinical trials, new research initiatives, and strong financial runway into Q2 2028. Manufacturing scalability and strategic partnerships support pipeline growth and capital efficiency.
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “...
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics Issues Letter to Stockholders
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics Earnings Call Transcript: Q3 2025
OpRegen clinical expansion, new partnerships, and manufacturing advances drive momentum, with a strong cash position and extended runway. Key programs in hearing loss and type 1 diabetes progress, while CIRM grant and milestone payments could further boost funding.
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “...
Lineage Cell Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
New initiatives include a type 1 diabetes program targeting manufacturing scale, and a hearing loss partnership with William Demant Invest. Lead therapy for dry AMD shows durable vision gains, while manufacturing advances enable scalable, pure cell production. Strategic partnerships and platform expansion drive future growth.
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics Earnings Call Transcript: Q2 2025
OpRegen continues to show durable vision gains in dry AMD, with strong external validation and partner support. Financials reflect a solid cash runway, increased revenue, and a non-cash impairment, while OPC1 advances with new delivery technology and manufacturing improvements.
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell ...
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Two Biotech Stocks Poised For Big Moves On Monday
Two Biotechs Poised For Big Moves On Monday (Sana Biotechnology | Lineage Cell Therapeutics)
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...
Lineage Cell Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025
OpRegen has shown unprecedented vision gains in dry AMD with GA, with durable benefits expected to persist in upcoming three-year data. The Roche partnership brings significant milestones and validates the approach, while Lineage’s manufacturing platform supports expansion into new cell therapy indications.
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell ...
Lineage Cell Therapeutics Earnings Call Transcript: Q1 2025
OpRegen continues to show durable benefits in dry AMD, with three-year data upcoming and strong partner support. Manufacturing breakthroughs enable large-scale, low-cost production, opening new partnership opportunities. OPC1 advances in spinal cord injury with improved delivery and manufacturing.
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic...